FDA-EMA Patient Engagement Cluster
WHAT: Cluster to share best practices involving patients along drug and biologic regulatory lifecycles
WHY: Broadened approach to advance and strengthen international collaboration
WHO: FDA and European Medicines Agency (EMA)
HOW: Meet up to four times per year
- Learn how their respective patients are engaged and involved
- Develop common goals of expanding future patient engagement activities